IV infusioncIAI Patient ≥18 yr 1 vial every 8 hr over 2 hr for 5-14 days. cUTI, including pyelonephritis 1 vial every 8 hr over 2 hr for 5-10 days. HAP, including VAP 1 vial every 8 hr over 2 hr for 7-14 days. Renal impairment CrCl 50-31 mL/min 1,000 mg/250 mg every 8 hr over 2 hr, 30-16 mL/min 750 mg/187.5 mg every 12 hr over 2 hr, 15-6 mL/min 750 mg/187.5 mg every 24 hr over 2 hr, <6 mL/min 750 mg/187.5 mg every 48 hr over 2 hr.
Hypersensitivity to ceftazidime pentahydrate, avibactam Na, Na carbonate or any cephalosporins. Immediate & severe hypersensitivity (eg, anaphylactic reaction) to any other β-lactams eg, penicillins, monobactams or carbapenems.
Discontinue use if severe hypersensitivity reactions occur. Hypersensitivity reactions to ceftazidime, other cephalosporins or any other β-lactam agents; history of non-severe hypersensitivity to other β-lactam agents. Discontinue treatment for Clostridium difficile. Overgrowth of non-susceptible organisms (eg, enterococci, fungi) due to prolonged use. Patients on controlled Na diet. Medicinal products known to inhibit peristalsis should not be given. Concurrent use w/ nephrotoxic medicinal products eg, aminoglycosides or potent diuretics (eg, furosemide). May cause +ve direct antiglobulin or Coombs' test; false +ve result w/ Cu reduction methods (eg, Benedict's, Fehling's, Clinitest). May affect ability to drive & use machines. Renal impairment. Not to be used during pregnancy. Interrupt breast-feeding. Childn <18 yr.
J01DD52 - ceftazidime and beta-lactamase inhibitor ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Sign Out
